MaximYankelevichMD

Pediatric Hematology & Oncology • Philadelphia, PA

Pediatric Neuro-Oncology

Section Chief, Oncology, St. Christopher's Hospital for Children; Professor of Pediatrics, Drexel University College of Medicine

Join to view full profile

Dr. Yankelevich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yankelevich's full profile

Already have an account?

Office
160 E Erie Ave
Philadelphia, PA 19134
Phone+1 215-427-5348

Summary

Maxim Yankelevich, MD, is a Pediatric Hematologist/Oncologist located in Philadelphia, PA, specializing in Pediatric Hematology & Oncology and subspecializing in Pediatric Neuro-Oncology and Neurofibromatosis. He completed his residency in Pediatrics at Children's Hospital of Michigan and a fellowship in Pediatric Hematology/Oncology at Baylor College of Medicine. He currently works as a Section Chief of Oncology at St. Christopher's Hospital for Children and serves as a Professor of Pediatrics at Drexel University College of Medicine. His research contributions include several influential publications, notably in the fields of neuro-oncology and cancer immunotherapy, and he has been involved in multiple clinical trials related to pediatric cancer treatments. Dr. Yankelevich has also been recognized as a Super Doctor by SuperDoctors.com.

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2003 - 2006
Children's Hospital of MichiganResidency, Pediatrics, 2000 - 2003
Omsk State Medical AcademyClass of 1992

Certifications & Licensure

PA State Medical License 2023 - 2026
MI State Medical License 2000 - 2025
NJ State Medical License 2019 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Start of enrollment: 2013 Aug 01
Terminated
Phase 3
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Start of enrollment: 2014 Nov 01
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Marrow-ablative consolidation chemotherapy and molecular targeted therapy delivered in a risk-adapted manner for newly diagnosed children with choroid plexus carcinoma:.
Maxim Yankelevich, Wafik Zaky, Lucie Lafay-Cousin, Diana Osorio, Jenny Adamski
Neuro-Oncology Advances. 2024-07-05
6 citations
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Maxim Yankelevich, Archana Thakur, Shakeel Modak, Roland Chu, Jeffrey Taub
Journal for Immunotherapy of Cancer. 2024-03-21
2 citations
Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
Maxim Yankelevich, Archana Thakur, Shakeel Modak, Roland Chu, Jeffrey Taub
Research Square. 2023-11-09

Lectures

Phase I study of OKT3 x hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors.
2019 ASCO Annual Meeting - 6/1/2019